Movers & Shakers: Stocks in focus: Reata Pharmaceuticals stock soars after FDA-drug approval; Novavax falls after vaccine maker issues ‘substantial doubts’ over future operations

Here are U.S. stocks in focus ahead of Wednesday’s trading session:

Reata Pharmaceuticals’ RETA stock shot up more than 177% on Wednesday morning after the Food and Drug administration approved a drug treatment for a disease called Friedreich’s ataxia, a rare inherited disease that causes damage to the nervous system.

Vaccine manufacturer…